Kenvue says post-hoc Phase III analysis links earlier 5% minoxidil use to higher hair regrowth in men with androgenetic alopecia

By Public Technologies
  • Kenvue outlined new clinical and preclinical findings slated for presentation at the EADV Congress in Vienna from Sept. 30 to Oct. 3, 2026.
  • Neutrogena studies indicated its niacinamide-based sunscreens improved visible acne-related marks and hydration, supporting broader multifunctional positioning in suncare.
  • Aveeno data suggested colloidal oat formulations helped reinforce skin-barrier recovery, with clinician feedback supporting add-on use in eczema care.
  • Regaine analysis linked earlier use of 5% minoxidil foam with stronger hair regrowth outcomes, supporting earlier-intervention messaging in male hair loss.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kenvue Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260930489298) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.